Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.4.2407

Post-diagnosis Soy Food Intake and Breast Cancer Survival: A Meta-analysis of Cohort Studies  

Chi, Feng (Department of Medical Oncology, Shengjing Hospital of China Medical University)
Wu, Rong (Department of Medical Oncology, Shengjing Hospital of China Medical University)
Zeng, Yue-Can (Department of Medical Oncology, Shengjing Hospital of China Medical University)
Xing, Rui (Department of Medical Oncology, Shengjing Hospital of China Medical University)
Liu, Yang (Department of Medical Oncology, Shengjing Hospital of China Medical University)
Xu, Zhao-Guo (Department of Medical Oncology, Shengjing Hospital of China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.4, 2013 , pp. 2407-2412 More about this Journal
Abstract
Background and Objectives: Data on associations between soy food intake after cancer diagnosis with breast cancer survival are conflicting, so we conducted this meta-analysis for more accurate evaluation. Methods: Comprehensive searches were conducted to find cohort studies of the relationship between soy food intake after cancer diagnosis and breast cancer survival. Data were analyzed with comprehensive meta-analysis software. Results: Five cohort studies (11,206 patients) were included. Pooling all comparisons, soy food intake after diagnosis was associated with reduced mortality (HR 0.85, 95%CI 0.77 0.93) and recurrence (HR 0.79, 95%CI 0.72 0.87). Pooling the comparisons of highest vs. lowest dose, soy food intake after diagnosis was again associated with reduced mortality (HR 0.84, 95%CI 0.71 0.99) and recurrence (HR 0.74, 95%CI 0.64 0.85). Subgroup analysis of ER status showed that soy food intake was associated with reduced mortality in both ER negative (highest vs. lowest: HR 0.75, 95%CI 0.64 0.88) and ER positive patients (highest vs. lowest: HR 0.72, 95%CI 0.61 0.84), and both premenopausal (highest vs. lowest: HR 0.78, 95%CI 0.69 0.88) and postmenopausal patients (highest vs. lowest: HR 0.81, 95%CI 0.73 0.91). In additioin, soy food intake was associated with reduced recurrence in ER negative (highest vs. lowest: HR 0.64, 95%CI 0.44 0.94) and ER+/PR+ (highest vs. lowest: HR 0.65, 95%CI 0.49 0.86), and postmenopausal patients (highest vs. lowest: HR 0.67, 95%CI 0.56 0.80). Conclusion: Our meta-analysis showed that soy food intake might be associated with better survival, especially for ER negative, ER+/PR+, and postmenopausal patients.
Keywords
Soy foods; breast neoplasms; survival; meta-analysis; receptor status; postmenopausal;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Boyapati SM, Shu XO, Zhi XR, et al (2005). Soyfood intake and breast cancer survival: A followup of the Shanghai Breast Cancer Study. Breast Cancer Res Treat, 92, 11-7.   DOI
2 Brooks JD, Thompson LU (2005). Mammalian lignans and genistein decrease the activities of aromatase and 17betahydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol, 94, 461-7.   DOI   ScienceOn
3 Caan BJ, Natarajan L, Parker B, et al (2011). Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev, 20, 854-8.   DOI   ScienceOn
4 Constantinou AI, Lantvit D, Hawthorne M, et al (2001). Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer, 41, 75-81.   DOI   ScienceOn
5 Constantinou AI, White BEP, Tonetti D, et al (2005). The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Europ J Cancer, 41, 647-54.   DOI   ScienceOn
6 Dong JY, Qin LQ (2011). Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat, 125, 315-23.   DOI   ScienceOn
7 Doyle C, Kushi LH, Byers T, et al (2006). Nutrition and physical activity during and after cancer treatment: An American Cancer Society guide for informed choices. CA Cancer J Clin, 56, 323-53.   DOI   ScienceOn
8 Enderlin CA, Coleman EA, Stewart CB, et al (2009). Dietary soy intake and breast cancer risk. Oncol Nurs Forum, 36, 531-9.   DOI   ScienceOn
9 Fink BN, Steck SE, Wolff MS, et al (2007). Dietary flavonoid intake and breast cancer survival among women on Long Island. Cancer Epidemiol Biomarkers Prev, 16, 2285-92.   DOI   ScienceOn
10 Guha N, Kwan ML, Quesenberry Jr CP, et al (2009). Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: The Life after Cancer Epidemiology study. Breast Cancer Res Treat, 118, 395-405.   DOI   ScienceOn
11 Harris PF, Remington PL, Trentham-Dietz A, et al (2002). Prevalence and Treatment of Menopausal Symptoms Among Breast Cancer Survivors. Journal of Pain and Symptom Management, 23, 501-9.   DOI   ScienceOn
12 Kang X, Zhang Q, Wang S, et al (2010). Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ, 182, 1857-62.   DOI   ScienceOn
13 Helferich WG, Andrade JE, Hoagland MS (2008). Phytoestrogens and breast cancer: a complex story. Inflammopharmacology, 16, 219-26.   DOI   ScienceOn
14 Jones JL, Daley BJ, Enderson BL, et al (2002). Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surg, 68, 575-7; discussion 577-8.
15 Ju YH, Doerge DR, Woodling KA, et al (2008). Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis, 29, 2162-8.   DOI   ScienceOn
16 Lacey M, Bohday J, Fonseka SM, et al (2005). Dose-response effects of phytoestrogens on the activity and expression of 3beta-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells. J Steroid Biochem Mol Biol, 96, 279-86.   DOI   ScienceOn
17 Li L, Li J, Yang K, et al (2010). Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer. Future Oncol, 6, 201-7.   DOI   ScienceOn
18 Liu B, Edgerton S, Yang X, et al (2005). Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res, 65, 879-86.
19 Messina MJ, Loprinzi CL (2001). Soy for breast cancer survivors: a critical review of the literature. J Nutr, 131, 3095S-108S.
20 Moon YJ, Wang X, Morris ME (2006). Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro, 20, 187-210.   DOI   ScienceOn
21 Morris KT, Johnson N, Homer L, Walts D (2000). A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg, 179, 407-11.   DOI   ScienceOn
22 Qin LQ, Xu JY, Wang PY, et al (2006). Soyfood intake in the prevention of breast cancer risk in women: a meta-analysis of observational epidemiological studies. J Nutr Sci Vitaminol (Tokyo), 52, 428-36.   DOI   ScienceOn
23 Nakata T, Takashima S, Shiotsu Y, et al (2003). Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients. J Steroid Biochem Mol Biol, 86, 455-60.   DOI   ScienceOn
24 Nechuta SJ, Caan BJ, Chen WY, et al (2012). Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr, 96, 123-32.   DOI
25 Pasqualini JR, Chetrite GS (2005). Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol, 93, 221-36.   DOI   ScienceOn
26 Santell RC, Chang YC, Nair MG, et al (1997). Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr, 127, 263-9.
27 Schwartz JA, Liu G, Brooks SC (1998). Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochem Biophys Res Commun, 253, 38-43.   DOI   ScienceOn
28 Shu XO, Zheng Y, Cai H, et al (2009). Soy food intake and breast cancer survival. JAMA, 302, 2437-43.   DOI   ScienceOn
29 Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283, 2008-12.   DOI   ScienceOn
30 Tanos V, Brzezinski A, Drize O, et al (2002). Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol, 102, 188-94.   DOI   ScienceOn
31 Wang TTY, Sathyamoorthy N, Phang JM (1996). Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis, 17, 271-5.   DOI   ScienceOn
32 Taylor CK, Levy RM, Elliott JC, et al (2009). The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev, 67, 398-415.   DOI   ScienceOn
33 Trock BJ, Hilakivi-Clarke L, Clarke R (2006). Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst, 98, 459-71.   DOI   ScienceOn
34 Velentzis LS, Woodside JV, Cantwell MM, et al (2008). Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer, 44, 1799-806.   DOI   ScienceOn
35 Zhang YF, Kang HB, Li BL, et al (2012). Positive effects of soy isoflavone food on survival of breast cancer patients in China. Asian Pac J Cancer Prev, 13, 479-82.   과학기술학회마을   DOI   ScienceOn